Hypothesis

Aging promotes senescence of gut enterochromaffin (EC) cells through accumulation of the microbial metabolite phenylacetic acid (PAA), which triggers oxidative DNA damage and activates the p16^INK4a‑RB pathway, thereby suppressing TPH1 expression and reducing serotonin (5‑HT) release. This senescence‑dependent loss of EC function contributes to age‑related gut dysmotility and downstream neuropsychiatric phenotypes.

Mechanistic rationale

• PAA, produced by certain commensals (e.g., Clostridia), has been shown to induce endothelial cell senescence during aging [[https://doi.org/10.1101/2023.11.17.567594]].
• EC cells express transporters for aromatic amino acids and may uptake PAA via similar mechanisms, leading to intracellular accumulation.
• PAA can generate reactive oxygen species via mitochondrial complex I inhibition, causing DNA double‑strand breaks that activate the senescence‑associated secretory phenotype (SASP) and upregulate p16^INK4a and p21^CIP1.
• Elevated p16^INK4a enforces RB‑mediated cell‑cycle arrest, which in EC cells correlates with reduced TPH1 transcription (observed in senescent fibroblasts where RB represses aryl hydrocarbon receptor activity) [[https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.837166/full]].
• Senescent EC cells also secrete IL‑6 and TGF‑β, further altering the local microbiome and shifting tryptophan metabolism toward kynurenine, compounding the substrate limitation described in aging [[https://pmc.ncbi.nlm.nih.gov/articles/PMC8257779/]].

Testable predictions

1. Marker correlation – In human colon biopsies from donors stratified by age (20‑35, 60‑75, >75 y), EC‑cell senescence (SA‑β‑gal^+, p16^INK4a^+, p21^CIP1^+) will increase with age and inversely correlate with TPH1 mRNA and 5‑HT content [[https://pubmed.ncbi.nlm.nih.gov/40812684/]].
2. Metabolite exposure – Isolated primary human EC cells treated with physiologic concentrations of PAA (10‑50 µM) will show increased SA‑β‑gal staining, ROS production, and p16^INK4a upregulation, accompanied by a ≥40 % drop in TPH1‑dependent 5‑HT release measured by ELISA.
3. Senolytic rescue – Co‑treatment with the BCL‑XL/BCL‑2 inhibitor navitoclax (1 µM) will reduce senescence markers and restore TPH1 expression and 5‑HT secretion to ≥80 % of untreated young‑cell levels, without affecting cell viability.
4. Microbiome transfer – Colon germ‑free mice colonized with microbiota from aged human donors exhibiting high PAA producers will develop EC‑cell senescence and reduced gut 5‑HT, whereas transplantation of a PAA‑low consortium (e.g., enriched Turicibacter sanguinis) will prevent these changes [[https://www.uclahealth.org/news/release/study-shows-how-serotonin-and-a-popular-antidepressant-affects-the-guts-microbiota]].
5. Regional specificity – Proximal colonic EC cells will show higher senescence indices than distal colon counterparts, reflecting regional differences in PAA accumulation and SCFA depletion.

Falsifiability

If any of the following observations are made, the hypothesis is weakened or refuted:

• No age‑related increase in EC‑cell senescence markers despite confirmed aging of the tissue.
• PAA exposure fails to induce senescence or alter TPH1/5‑HT in human EC cells.
• Senolytic treatment does not rescue TPH1 expression or 5‑HT release despite clearing senescence markers.
• Microbiota from aged donors does not transmit the phenotype to germ‑free mice, or PAA‑low microbiota fails to protect.

Implications

Confirming PAA‑driven EC senescence would reveal a direct microbial‑metabolite link to the gut‑brain axis in aging and suggest that targeted senolytics or microbiome‑based strategies (e.g., prebiotics that suppress PAA producers) could restore serotonergic signaling and ameliorate age‑related motility and mood disorders.